SEC Comment Letter 0000000000-25-011911 to Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc.
Date: Dec. 31, 2025 · CIK: 0001937993 · Accession: 0000000000-25-011911
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292444
Letter
December 31, 2025 Quang Pham Chairman and Chief Executive Officer Cadrenal Therapeutics, Inc. 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 Re:Cadrenal Therapeutics, Inc. Registration Statement on Form S-1 Filed December 29, 2025 File No. 333-292444 Dear Quang Pham: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jamie L. Plisner, Esq.
Show Raw Text
December 31, 2025
Quang Pham
Chairman and Chief Executive Officer
Cadrenal Therapeutics, Inc.
822 A1A North, Suite 306
Ponte Vedra, Florida 32082
Re:Cadrenal Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 29, 2025
File No. 333-292444
Dear Quang Pham:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jamie L. Plisner, Esq.